{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:09:50Z","timestamp":1778821790179,"version":"3.51.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer treatment-induced thrombocytopenia (CTIT) is a common adverse effect of cancer therapy. CTIT increases the risk of bleeding, prolongs hospital stays, raises medical costs, and can negatively impact anti-tumor treatment outcomes, potentially leading to patient death. Therefore, it is crucial to initiate platelet-boosting therapy in a timely manner based on the individual circumstances of patients experiencing CTIT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who developed cancer treatment-induced thrombocytopenia and received Rh-TPO treatment from January 2023 and December 2023 were obtained for establishing the dataset. With absolute platelets increase as the outcome variable, univariate analysis was performed to screen out statistically significant factors, and 18 clinical variables were selected as initial features. The least absolute shrinkage and selection operator (LASSO) regression analysis was then used to identify the most important features. Based on this, a stacking ensemble model was constructed using cross-validation with out-of-fold predictions to prevent information leakage, and the predictive performance of the model was evaluated. Finally, the SHapley Additive exPlanations (SHAP) algorithm was used to explain the model, and a visual analysis of the features was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 400 inpatients who developed cancer treatment-induced thrombocytopenia and received Rh-TPO treatment were included, of which 280 inpatients were assigned to the training set and 1,20 to the testing set. After LASSO regression screening, the study identified 7 key features: ethnicity, height, baseline serum creatinine, pre-chemotherapy platelet count, follow-up days after chemotherapy, platelet count before Rh-TPO, and duration of Rh-TPO treatment. We compared the performance of different machine learning models and selected the best three models as base models. Combined with Linear Regression as the meta-learner, we built a stacking ensemble model using 3-fold cross-validation with out-of-fold predictions. The stacking ensemble model showed best prediction ability compared to independent models with R\u00b2 of 0.77 (training) and 0.74 (testing), MAE of 6.39 (training) and 8.34 (testing), MSE of 62.17 (training) and 97.70 (testing), RMSE of 7.88 (training) and 9.88 (testing), and MAPE of 0.09 (training) and 0.12 (testing). SHAP analysis showed that pre-chemotherapy PLT value and the follow-up days after chemotherapy were the important features affecting the prediction results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The predictive model developed in this study could be beneficial for accurately predicting the improvement in platelet count in patients with CTIT who use Rh-TPO, facilitating timely assistance for patients in avoiding the risks caused by a drop in platelet count in a timely manner.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1751214","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:32Z","timestamp":1778819312000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting the efficacy of recombinant human thrombopoietin in treating cancer therapy-related thrombocytopenia: based on stacking ensemble methods"],"prefix":"10.3389","volume":"16","author":[{"given":"Kun","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Peking University Cancer Hospital\/Affiliated Cancer Hospital of Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia, China"]},{"name":"The Laboratory for Inheritance and Development of Integrated Chinese (Mongolian) and Western Medicine in Anti-Tumor Therapy, Peking University Cancer Hospital\/Affiliated Cancer Hospital of Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Huangfu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Pathology Department, Peking University Cancer Hospital\/Affiliated Cancer Hospital of Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University Cancer Hospital\/Affiliated Cancer Hospital of Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiwen","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Medical Simulated Center, Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongwu","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenfei","family":"Wang","sequence":"additional","affiliation":[{"name":"The Laboratory for Inheritance and Development of Integrated Chinese (Mongolian) and Western Medicine in Anti-Tumor Therapy, Peking University Cancer Hospital\/Affiliated Cancer Hospital of Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061169","article-title":"Challenges and advances in managing thrombocytopenic cancer patients","volume":"10","author":"Leader","year":"2021","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35292","article-title":"A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: a multicenter, cross-sectional study","volume":"130","author":"Chen","year":"2024","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3781\/j.issn.1000-7431.2021.2111-0882","article-title":"Consensus on clinical management of cancer therapy-related thrombocytopenia","volume":"41","year":"2021","journal-title":"Tumor"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic Malignancies","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"B5","first-page":"1","article-title":"Cancer Therapy-Induced Thrombocytopenia. Beijing: People's Medical Publishing House","year":"2024"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20230409-00575","article-title":"Consensus on the clinical diagnosis, treatment and prevention of cancer treatment-induced thrombocytopenia in China (2023 edition)","volume":"103","year":"2023","journal-title":"Natl Med J China"},{"key":"B7","year":"","journal-title":"NCCN Clinical Practice Guidelines in Oncology. Hematopoietic Growth Factors. Version 3.2024-January 30, 2024"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/141134","article-title":"Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia","volume":"17","author":"Li","year":"2021","journal-title":"Arch Med Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn371439-20230730-00125","article-title":"The efficacy and safety of recombinant human thrombopoietin in the treatment of thrombocytopenia caused by tumor radiotherapy","volume":"50","author":"Wang","year":"2023","journal-title":"J Int Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2174\/0113892029313473240919105819","article-title":"CDT1 is a potential therapeutic target for the progression of NAFLD to HCC and the exacerbation of cancer","volume":"26","author":"He","year":"2025","journal-title":"Curr Genomics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429380394250217093030","article-title":"Exploring the immune-related molecular mechanisms underlying the comorbidity of temporal lobe epilepsy and major depressive disorder through integrated data set analysis","volume":"17","author":"Yan","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/0109298665342261240912105111","article-title":"Immunoproteomics: approach to diagnostic and vaccine development.Protein","volume":"31","author":"Gomase","year":"2024","journal-title":"Pept Lett"},{"key":"B13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/0113892029291661241114055924","article-title":"Bioinformatics analysis of lactylation-related biomarkers and potential pathogenesis mechanisms in age-related macular degeneration","volume":"26","author":"Gui","year":"2025","journal-title":"Curr Genomics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11061096","article-title":"Forecasting the walking assistance rehabilitation level of stroke patients using artificial intelligence","volume":"11","author":"Seo","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12967-022-03364-0","article-title":"Machine learning for the prediction of acute kidney injury in patients with sepsis","volume":"20","author":"Yue","year":"2022","journal-title":"J Transl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.107289","article-title":"Machine learning algorithms to predict major adverse cardiovascular events in patients with diabetes","volume":"164","author":"Abegaz","year":"2023","journal-title":"Comput Biol Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.11669\/cpj.2023.11.011","article-title":"Prediction of nausea and vomiting duration in patients with tumours induced by cisplatin chemotherapy based on machine learning","volume":"58","author":"Zhang","year":"2023","journal-title":"Chin Pharm J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.12015\/issn.1674-8034.2024.03.016","article-title":"Radiomics based on combined machine learning models for prediction of the response to neoadjuvant chemotherapy in mass enhancement breast cancer using magnetic resonance imaging","volume":"15","author":"Yue","year":"2024","journal-title":"Chin J Magn Reson Imaging"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233678","article-title":"Deep learning-based survival prediction for multiple cancer types using histopathology images","volume":"15","author":"Wulczyn","year":"2020","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"18040","DOI":"10.1038\/s41598-020-74921-0","article-title":"Ensemble transfer learning for the prediction of anti-cancer drug response","volume":"10","author":"Zhu","year":"2020","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.aej.2024.06.036","article-title":"Enhanced heart disease prediction in remote healthcare monitoring using IoT-enabled cloud-based XGBoost and Bi-LSTM","volume":"105","author":"Alzakari","year":"2024","journal-title":"Alexandria Eng J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"107226","DOI":"10.1016\/j.compbiolchem.2020.107226","article-title":"Molecular docking, quantum chemical computational and vibrational studies on bicyclic heterocycle \"6-nitro-2,3-dihydro-1,4-benzodioxine\": anti-cancer agent","volume":"86","author":"Shafi","year":"2020","journal-title":"Comput Biol Chem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1109\/MCAS.2006.1688199","article-title":"Ensemble based systems in decision making","volume":"6","author":"R Polikar","year":"2006","journal-title":"IEEE Circuits Syst Mag"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1023\/b:mach.0000015881.36452.6e","article-title":"Is combining classifiers with stacking better than selecting the best one","volume":"54","author":"D\u017eeroski","year":"2004","journal-title":"Mach Learn"},{"key":"B25","article-title":"On over-fitting in model selection and subsequent selection bias in performance evaluation","volume":"11","author":"Cawley","year":"2010","journal-title":"J Mach Learn Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.701539","article-title":"A real-world observation of eltrombopag and recombinant human thrombopoietin (rhTPO) in lymphoma patients with chemotherapy induced thrombocytopenia","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1053\/shem.2000.7391","article-title":"Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia","volume":"37","author":"Vadhan-Raj","year":"2000","journal-title":"Semin Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.003","article-title":"Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia","volume":"21","author":"Vadhan-Raj","year":"2003","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1260487","article-title":"Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently","volume":"10","author":"Yassin","year":"2023","journal-title":"Front Cardiovasc Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1751214\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:37Z","timestamp":1778819317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1751214\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1751214"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1751214","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1751214"}}